|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arbyn M, Weiderpass E, Bruni L, de Sanjosé
S, Saraiya M, Ferlay J and Bray F: Estimates of incidence and
mortality of cervical cancer in 2018: A worldwide analysis. Lancet
Glob Health. 8:e191–e203. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vinh-Hung V, Bourgain C, Vlastos G, Cserni
G, De Ridder M, Storme G and Vlastos AT: Prognostic value of
histopathology and trends in cervical cancer: A SEER population
study. BMC Cancer. 7:1642007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Denny L, Adewole I, Anorlu R, Dreyer G,
Moodley M, Smith T, Snyman L, Wiredu E, Molijn A, Quint W, et al:
Human papillomavirus prevalence and type distribution in invasive
cervical cancer in sub-Saharan Africa. Int J Cancer. 134:1389–1398.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu XX, Zhou JS, Yuan SH, Yu H and Lou HM:
Distribution of HPV genotype in invasive cervical carcinoma and
cervical intraepithelial neoplasia in Zhejiang province, southeast
China: Establishing the baseline for surveillance. Int J Environ
Res Public Health. 12:10794–10805. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McDowell M, Pardee DJ, Peitzmeier S,
Reisner SL, Agénor M, Alizaga N, Bernstein I and Potter J: Cervical
cancer screening preferences among trans-masculine individuals:
Patient-collected human papillomavirus vaginal swabs versus
provider-administered pap tests. LGBT Health. 4:252–259. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bosgraaf RP, Ketelaars PJ, Verhoef VM,
Massuger LF, Meijer CJ, Melchers WJ and Bekkers RL: Reasons for
non-attendance to cervical screening and preferences for HPV
self-sampling in Dutch women. Prev Med. 64:108–113. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heymann JA and Hinshaw JE: Dynamins at a
glance. J Cell Sci. 122((Pt 19)): 3427–3431. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Raja SA, Shah STA, Tariq A, Bibi N, Sughra
K, Yousuf A, Khawaja A, Nawaz M, Mehmood A, Khan MJ and Hussain A:
Caveolin1 and dynamin2 overexpression is associated with the
progression of bladder cancer. Oncol Lett. 18:219–226.
2019.PubMed/NCBI
|
|
11
|
Meng J: Distinct functions of dynamin
isoforms in tumorigenesis and their potential as therapeutic
targets in cancer. Oncotarget. 8:41701–41716. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Inokawa Y, Nomoto S, Hishida M, Hayashi M,
Kanda M, Nishikawa Y, Takeda S, Fujiwara M, Koike M, Sugimoto H, et
al: Dynamin 3: A new candidate tumor suppressor gene in
hepatocellular carcinoma detected by triple combination array
analysis. Onco Targets Ther. 6:1417–1424. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Z, Chen C, Guo W, Zheng S, Sun Z and
Geng X: DNM3 attenuates hepatocellular carcinoma growth by
activating P53. Med Sci Monit. 22:197–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gu C, Yao J and Sun P: Dynamin 3
suppresses growth and induces apoptosis of hepatocellular carcinoma
cells by activating inducible nitric oxide synthase production.
Oncol Lett. 13:4776–4784. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res.
45(W1):W98–W102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using quantitative PCR and the
2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trepat X, Chen Z and Jacobson K: Cell
migration. Compr Physiol. 2:2369–2392. 2012.PubMed/NCBI
|
|
18
|
Dietrich JB: Apoptosis and anti-apoptosis
genes in the Bcl-2 family. Arch Physiol Biochem. 105:125–135.
1997.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Brambilla E, Negoescu A, Gazzeri S,
Lantuejoul S, Moro D, Brambilla C and Coll JL: Apoptosis-related
factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am J
Pathol. 149:1941–1952. 1996.PubMed/NCBI
|
|
20
|
Levesley J, Steele L, Bruning-Richardson
A, Davison A, Zhou J, Ding C, Lawler S and Short SC: Selective
BCL-XL inhibition promotes apoptosis in combination with MLN8237 in
medulloblastoma and pediatric glioblastoma cells. Neuro Oncol.
20:203–214. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Suarez-Carmona M, Lesage J, Cataldo D and
Gilles C: EMT and inflammation: Inseparable actors of cancer
progression. Mol Oncol. 11:805–823. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma Y, Guan L, Han Y, Zhou Y, Li X, Liu Y,
Zhang X, Zhang W, Li X, Wang S and Lu W: siPRDX2-elevated DNM3
inhibits the proliferation and metastasis of colon cancer cells via
AKT signaling pathway. Cancer Manag Res. 11:5799–5811. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang JK, Yang JP, Tong J, Jing SY, Fan B,
Wang F, Sun GZ and Jiao BH: Exosomal miR-221 targets DNM3 to induce
tumor progression and temozolomide resistance in glioma. J
Neurooncol. 131:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
